EyePoint completes enrollment in two phase 3 DME drug trials

July 30, 2026 7:01 AM

EyePoint, Inc. (NASDAQ: EYPT) announced it has completed enrollment in two global Phase 3 clinical trials — COMO and CAPRI ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found